Phase (Ph) I evaluation of the dolastatin analogue synthadotin (SYN-D; ILX651): Pooled data analysis of three alternate schedules in patients (pts) with advanced solid tumors
L. A. Hammond(Beth Israel Deaconess Medical Center), Eric K. Rowinsky(The University of Texas at San Antonio), Joseph P. Eder(Yale Cancer Center), Eric H. Rubin(Rutgers Cancer Institute), Akira Mita(Mary Crowley Cancer Research Center), Casey Cunningham(Massachusetts General Hospital), J. Weiß(University of North Carolina at Chapel Hill), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), E. M. Hersh(Arizona Oncology), Francis Ruvuna(Mary Crowley Cancer Research Center)
Cited by 8
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k